DexCom Inc (DXCM)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 63.52% | 64.29% | 64.38% | 64.88% | 65.18% | 66.21% | 67.98% | 70.00% | 72.01% | 72.83% | 72.90% | 71.43% | 70.18% | 67.84% | 66.08% | 65.54% | 65.29% | 64.90% | 64.56% | 64.39% |
| Operating profit margin | 16.59% | 14.97% | 14.11% | 13.23% | 13.54% | 9.72% | 9.12% | 10.54% | 11.39% | 16.73% | 16.76% | 16.29% | 16.42% | 16.93% | 15.60% | 12.24% | 9.97% | -9.51% | -13.97% | -15.33% |
| Pretax margin | 19.72% | 17.67% | 15.85% | 13.97% | 13.53% | 9.63% | 8.84% | 10.15% | 11.00% | 18.34% | 17.87% | 16.55% | 16.33% | 13.56% | 12.57% | 9.85% | 7.30% | -12.83% | -14.15% | -11.65% |
| Net profit margin | 15.03% | 11.15% | 11.26% | 9.74% | 11.81% | 8.91% | 8.86% | 10.40% | 9.29% | 28.71% | 30.05% | 30.63% | 30.14% | 13.17% | 12.33% | 9.51% | 7.09% | -13.16% | -14.36% | -11.71% |
The gross profit margin of Dexcom Inc has shown consistency in the range of 63% to 68% over the past eight quarters, indicating the company's ability to generate profits after accounting for the cost of goods sold.
The operating profit margin has also remained relatively stable, ranging from 9% to 17%. This suggests that Dexcom has been effective in controlling its operating expenses while generating operating income.
The pretax margin has fluctuated between 7% and 20%. This ratio reflects the company's ability to generate profits before accounting for taxes, with the Q4 2023 pretax margin reaching a high of 19.61%.
Dexcom's net profit margin has ranged from 7% to 15% over the same period. This ratio indicates the company's overall profitability after all expenses, including taxes, have been taken into account.
Overall, Dexcom has demonstrated consistent profitability performance, as reflected in its gross, operating, pretax, and net profit margins, with slight fluctuations observed across different quarters.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 9.54% | 7.67% | 6.57% | 7.20% | 7.26% | 5.44% | 4.55% | 5.17% | 5.39% | 7.73% | 7.66% | 7.10% | 6.98% | 7.75% | 7.35% | 7.77% | 5.94% | -5.66% | -8.03% | -8.61% |
| Return on assets (ROA) | 8.64% | 5.72% | 5.24% | 5.30% | 6.33% | 4.98% | 4.41% | 5.10% | 4.40% | 13.26% | 13.73% | 13.36% | 12.81% | 6.03% | 5.81% | 6.04% | 4.22% | -7.84% | -8.25% | -6.58% |
| Return on total capital | 16.23% | 13.14% | 11.54% | 12.76% | 12.30% | 7.45% | 5.88% | 6.51% | 7.36% | 10.41% | 10.37% | 9.71% | 9.80% | 9.96% | 9.12% | 10.66% | 8.47% | -6.28% | -7.25% | -5.69% |
| Return on equity (ROE) | 26.18% | 16.62% | 17.02% | 13.10% | 16.01% | 13.38% | 10.20% | 11.77% | 10.62% | 33.13% | 35.24% | 35.65% | 35.42% | 15.41% | 15.12% | 15.83% | 11.45% | -22.41% | -24.77% | -19.41% |
Dexcom Inc's profitability ratios have shown a favorable trend over the quarters, indicating improved efficiency in generating profits from its assets and capital.
- Operating return on assets (Operating ROA) has consistently increased from 5.75% in Q3 2022 to 9.57% in Q4 2023. This indicates that the company's operational performance in utilizing its assets to generate profits has been improving steadily.
- Return on assets (ROA) has shown fluctuations but generally increased from 4.69% in Q3 2022 to 8.64% in Q4 2023. This ratio reflects the overall profitability of the company relative to its total assets.
- Return on total capital has also exhibited an upward trend, reaching 13.15% in Q4 2023 from 5.86% in Q2 2022. This metric highlights the efficiency in generating profits from both equity and debt capital invested in the business.
- Return on equity (ROE) has notably improved over the quarters, showing a consistent increase from 8.85% in Q2 2022 to 26.18% in Q4 2023. This indicates the company's ability to generate profits from the shareholders' equity investment.
Overall, Dexcom Inc's profitability ratios demonstrate an upward trajectory, suggesting enhanced profitability and operational effectiveness over the analyzed period.